Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Preferred Stock Liabilities (2021 - 2024)

Senti Biosciences (SNTI) has 3 years of Preferred Stock Liabilities data on record, last reported at $25.1 million in Q4 2024.

  • For Q4 2024, Preferred Stock Liabilities changed N/A year-over-year to $25.1 million; the TTM value through Dec 2024 reached $25.1 million, changed N/A, while the annual FY2024 figure was $25.1 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $25.1 million in Q4 2024 per SNTI's latest filing, down from $171.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $171.8 million in Q2 2021 and bottomed at $25.1 million in Q4 2024.
  • Average Preferred Stock Liabilities over 3 years is $134.1 million, with a median of $171.8 million recorded in 2021.
  • The widest YoY moves for Preferred Stock Liabilities: up 86.86% in 2022, down 86.86% in 2022.
  • A 3-year view of Preferred Stock Liabilities shows it stood at $171.8 million in 2021, then changed by 0.0% to $171.8 million in 2022, then plummeted by 85.39% to $25.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Preferred Stock Liabilities were $25.1 million in Q4 2024, $171.8 million in Q1 2022, and $171.8 million in Q4 2021.